New Two-Pronged attack on Tough-to-Treat prostate cancer
NCT ID NCT06909825
Summary
This study is testing a new combination treatment for men with an advanced form of prostate cancer that has spread and no longer responds to standard hormone therapy. It combines a radioactive drug that seeks out cancer cells with a pill that blocks cancer's ability to repair itself. The goal is to find the safest and most effective dosing schedule to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, 5037, Australia
-
Macquarie University Hospital
Macquarie Park, New South Wales, 2113, Australia
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Conditions
Explore the condition pages connected to this study.